Press Releases

Circassia Announces Duaklir® New Drug Application (NDA) and Tudorza® Supplemental NDA Accepted for Review by FDA

Click here to download full press release – PDUFA target action date of 31 March 2019 confirmed for both filings – Oxford, UK – 13 August 2018: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR),...

View details

Circassia Announces Submission of Duaklir® New Drug Application and Tudorza® Supplemental New Drug Application in the United States

Click here to download full press release – Duaklir® NDA for treatment of chronic obstructive pulmonary disease (COPD) – – Tudorza® sNDA for inclusion of COPD exacerbation reduction and cardiovascular safety data in label –...

View details

Circassia Announces Positive Data Presented at 2018 American Thoracic Society Conference from Tudorza® Phase IV and Duaklir® Phase III Studies

Click here to download full press release Oxford, UK – 22 May 2018: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces the presentation of...

View details

Preliminary Results for the Year Ended 31 December 2017

Click here to download the full 2017 preliminary results statement – Strong NIOX® sales growth – – Good progress in AstraZeneca US commercial partnership – – Compelling clinical data for Tudorza® and Duaklir® – –...

View details

Circassia Receives Innovative Technology Contract from Vizient, Inc. for NIOX VERO® Asthma Management Products

Click here to download full press release Oxford, UK – 8 February 2018: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces that it has...

View details

Circassia Announces Tudorza® Successfully Met Both Primary Endpoints in ASCENT Phase IV Study in Chronic Obstructive Pulmonary Disease

Click here to download full press release – Significantly reduced COPD exacerbations – – Demonstrated favourable cardiovascular safety profile similar to placebo – – Circassia’s partner AstraZeneca plans to file data for inclusion in US...

View details

Circassia Welcomes New NICE Guidelines Recommending Use of FeNO Testing in Asthma Diagnosis

Click here to download full press release Oxford, UK – 29 November 2017: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, welcomes the publication of new...

View details

Interim Results for the Six Months Ended 30 June 2017

Click here to download the full 2017 interim results statement – Strong NIOX® sales growth – – Duaklir® NDA filing on track following positive phase III results – – AstraZeneca US commercial collaboration progressing well...

View details

Circassia Announces European Launch of NIOX VERO® Nasal Mode for Screening of Primary Ciliary Dyskinesia

Click here to download full press release Oxford, UK – 12 September 2017: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces the European launch...

View details

Circassia Announces Duaklir® Successfully Met Primary Endpoints in AMPLIFY Phase III Study in Chronic Obstructive Pulmonary Disease

Click here to download the full press release – NDA submission planned H1 2018 by partner AstraZeneca – – Filing supported by positive results from ACHIEVE dose-ranging study – – Circassia has exclusive commercialisation rights...

View details